<DOC>
	<DOCNO>NCT02120092</DOCNO>
	<brief_summary>Background : Coronary heart disease common cause death industrialized country . Revascularisation percutaneous coronary angioplasty thrombolysis main principle treatment acute coronary syndrome . To inhibit platelet activity patient routinely give acetylsalicylic acid ( ASA ) clopidogrel , second-generation thienopyridine . Recently , ticagrelor , novel cyclopentyl-triazolo-pyrimidine several pharmacological advantage , demonstrate great efficacy high bleeding risk clopidogrel . Coronary thrombus formation complex process antithrombotic mechanism platelet function inhibitor incompletely understood . Studies venous blood vitro truly reflect vivo circumstance often take account flow condition interaction endothelium , blood cell coagulation factor . Results animal model may relevant prothrombotic mechanism human . We develop technique allows investigate hemostatic system activation directly site thrombus formation vivo human . Aim : compare inhibitory effect clopidogrel ticagrelor ( without concomitant ASA ) hemostatic system activation circumstance close vivo situation . Design , patient intervention : prospective , randomize , double-blind , placebo control parallel-group study 2x2 factorial design include 112 healthy volunteer randomise 4 treatment arm : ticagrelor clopidogrel + placebo , ticagrelor clopidogrel + ASA . Outcome variable : Indicators platelet coagulation activation [ ß-thromboglobulin thromboxane B2 well prothrombin fragment F1+2 D-Dimer , respectively ] measure several time point 8 day period venous blood blood emerge standardized injury microvasculature determine bleeding time ( shed blood ) . Statistical consideration : Sample size calculation base percent change main outcome variable `` β-TG shed blood '' baseline 2 hour treatment start . Statistical analysis base full analysis set , include randomized subject receive least start dose study medication blood collection baseline 2 hour treatment start perform .</brief_summary>
	<brief_title>The Effect Clopidogrel Ticagrelor With Without Acetylsalicylic Acid ( ASA ) Hemostatic System Activation Site Plug Formation Vivo Man</brief_title>
	<detailed_description />
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<mesh_term>Hemostatics</mesh_term>
	<criteria>young , healthy male history bleed medication know intolerance study drug ( )</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>ACS , Acute coronary syndrome</keyword>
</DOC>